Acute B Hepatitis after Hepatitis C Virus Therapy with Direct Acting Antivirals in a Co-infected Patient with HIV

María Paniagua García, Inmaculada López Hernández, Felipe Fernández Cuenca and María José Rios Villegas

Unit Clinical Management of Infectious Diseases, Microbiology and Preventive Medicine, Virgen Macarena University Hospital and Virgen del Rocio-IBIS, Sevilla, Spain

Corresponding author: María Paniagua García, Unit Clinical Management of Infectious Diseases, Microbiology and Preventive Medicine, Virgen Macarena University Hospital and Virgen del Rocio-IBIS, Sevilla, Spain, Tel: +34 955 008 286; E-mail: maria.paniagua89@gmail.com

Received date: September 20, 2016; Accepted date: October 25, 2016; Published date: November 1, 2016

Abstract

Up until now, few cases of HBV reactivation after HCV therapy with new direct acting antivirals have been communicated, the majority of them without clinical repercussion. We present a case of fulminant hepatic failure for HBV reactivation in a patient infected with human immunodeficiency virus, after HCV therapy with DAAs.

Keywords: Hepatitis C virus; Hepatitis B virus reactivation; Human immunodeficiency virus; Direct acting antivirals

Introduction

Hepatitis C virus (HCV) infection is one of the major causes of chronic hepatic disease, generating a variable long-term impact, from minimal histological changes to advanced fibrosis, with or without hepatocellular carcinoma [1]. Globally, there are approximately 160 millions people chronically infected with HCV. The introduction of direct acting antivirals (DAAs) has meant an improvement in HCV management, both in naïve and previously treated without success patients. These are oral drugs that directly inhibit the HCV replication cycle, and they lead to higher sustained virological response compared with interferon-based regimens, with a shorter duration and less adverse events.

Frequently, HCV patients are co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV), which increase the risk of progression into cirrhosis and hepatic decompensation. It has been estimated [2] that 400 millions people are HBV carriers globally, 75% of whom are from Asia and West Pacific.

Within HIV patients, approximately [3] 25% are also infected with HCV, with higher rates (approximately 75%) among parenteral drugs users and infected through transfusion. 10% of HIV patients are co-infected with HBV, with high differences between regions. However, due to the lack of big scale population studies, the exact number of patients co-infected HCV-HBV and HCV-HBV-HIV is unknown.

In HCV and HBV co-infected patients, HCV elevated viral load usually is associated with low HBV levels [4], independently of HIV infection. HBV reactivation is a well-known process in the context of immunosuppression [5], and there have been communicated punctual increases of HBV DNA after treatment with pegylated interferon and ribavirin, without any clinical repercussion, where it seems that interferon is active against both viruses.

In this context we present a case of HBV reactivation after HCV treatment with DAAs (Ledipasvir/Sofosbuvir), in a patient with a past HBV infection, chronic HCV infection genotype 1a and HIV infection.

Case Report

The case we show is a 53 years-old patient, smoker, former parenteral drug user and with history of arterial hypertension, chronic pulmonary obstructive disease GOLD (Global Initiative for Obstructive Lung Diseases) IV and peripheral artery disease. The patient was diagnosed of HIV in 1998 after being diagnosed of a pulmonary tuberculosis and possible Pneumocystis jirovecii pneumonia, with an adequate response to antiretroviral treatment. He also had a chronic HCV infection genotype 1a and a history of a past HBV infection with positive core IgG antibody (anti-HBc IgG), both surface antigen (HBsAg) and antibody (HBsAb) negatives, with undetectable DNA-HBV, prior to DAA treatment.

Regarding HIV infection, the patient has followed different therapeutic schedules (Figure 1) with plenty of failure and resistance development, and a remarkable resistance to Zidovudine and Lamivudine, Nevirapine hepatotoxicity and intolerance to Efavirenz. In October 2011 treatment with Tenofovir (TDF), Abacavir and Atazanavir/Ritonavir was started, but later, due to worsening in renal function, TDF was removed and treatment was simplified to Darunavir/Cobicistat, with an excellent adhesion and response, undetectable viral load and T CD4 lymphocytes between 500-800/mm³ since then (800/mm³ CD4 lymphocytes in last control, before HCV treatment with DAAs).

In October 2013 HCV treatment was started, following the schedule pegylated interferon (PEG-IFN) alpha-2a, 180 mcg, one injection weekly, and Ribavirin 1000 mg daily (3-0-2), reaching a HCV viral load fall of 3 logarithms in week 4 of treatment. In that moment we considered adding first generation direct antivirals (Telaprevir), but the patient had bad tolerance to PEG-IFN and refused to continue with treatment.

In October 2015 HCV treatment was completed with a higher viral load fall of 4.5 logarithms and sustained virological response, making, after consultation with the patient, to continue the treatment with Peginterferon and Ribavirin, in the absence of treatment tolerance.

In October 2016, 4 weeks after completing the HCV treatment, the patient was admitted with severe liver failure and isolated acute B hepatitis, after being treated with Peginterferon and Ribavirin. A biopsy was performed showing a chronic hepatitis grade 3 and advanced fibrosis, no evidence of necrosis, no signs of acute hepatitis, no signs of cirrhosis and no signs of HBV reactivation.

In February 2017, the patient was admitted with acute respiratory failure and severe liver failure. A liver biopsy was performed showing a severe acute hepatitis grade 5, with severe necrosis and advanced fibrosis. The acute hepatitis was confirmed by histological examination of the liver biopsy, showing severe necrosis, advanced fibrosis and no signs of HBV reactivation.
In December 2015 the patient had a HCV viral load of 2,181,330.11 UI/mL, with a hepatic elastometry of 12 Kpa, so we decided to start treatment with DAAs: Sofosbuvir and Ledipasvir during 12 weeks. In week 2 of treatment the viral load had descended to 284.51 UI/mL, 30.45 UI/mL in week 4, and less of 15 UI/ml from week 8, reaching sustained viral response at week 4 post treatment.

A month later, the patient consulted for abdominal pain, nausea and marked jaundice, with a total bilirubin of 10.98 mg/dl, direct bilirubin of 8.75 mg/dl, glutamic-oxalacetic transaminase (GOT) of 1025.40 UI/L, glutamate-pyruvate transaminase (GPT) of 642 UI/L with International Normalized Ratio (INR) of 1.30. HBV viral load was 6, 193, 455.96 UI/ml, with a serologic pattern of positive HBsAg, anti-HBc IgM and HBeAg. HCV viral load was still undetectable, and hepatic D virus was negative. Therefore we were facing an acute B hepatitis.

Treatment with Entecavir against HBV was initiated (TDF had previously been suspended for renal function worsening), however clinical evolution was unfavourable, with ascites, encephalopathy and INR and transaminases increase, so the patient was included into Care Intensive Unit, were he continued with a bad clinical evolution and died due to acute hepatic failure.

As we were facing a case of acute hepatitis in the context of HBV reactivation after DAA treatment in a co-infected HCV and HBV patient, we requested HBV viral load from the samples collected during HCV treatment. This way we obtained an undetectable HBV viral load at the beginning of the treatment and at week 2, but that was progressively increasing to 98.80 UI/mL at week 8 of treatment and to 82,700 UI/mL at week 4 post treatment (Figure 2).

The risk of HBV reactivation in the context of immunosuppressive therapy (chemotherapy, biological treatment -specially Rituximab and AntiTNF-, solid organ transplantation) is well known [5] and this supposes a serious complication. In these cases it is recommended to systematically determine HBsAg and anti-HBc and to start an adequate antiviral treatment in positive HBsAg patients and positive anti-HBc with negative HBsAg patients, due to the risk of seroconversion in these cases.

However, some cases of HBV reactivation in the context of treatment with DAAs in co-infected HCV an HBV are being communicated [6-8], the majority of them are asymptomatic and with no clinical repercussion, with a good response to nucleoside/nucleotide analogues, except for one 59 years old patient [9] genotype 1b, with a positive anti-HBc and undetectable HBV DNA prior to HCV treatment with DAAs (Simeprevir, Sofosbuvir and Ribavirin), who developed at week 11 of treatment a fulminant acute hepatitis that required hepatic transplantation.

Also, in a recent study [10] with a low number of patients to evaluate the efficacy of treatment with Sofosbuvir and Ledipasvir 12 weeks in coinfected HBV and HCV genotype 1 patients, DNA HBV increments of 88% were notified, none of them higher than 20.000 UI/mL, and with no association to neither acute hepatitis and need of treatment.

Usually, in co-infected HCV and HBV patients, HBV DNA is low or undetectable [4], but it can fluctuate, and HCV is the principal cause of chronic hepatic activity. Different theories [11] to explain HBV replication inhibition in co-infected patients had been proposed. The first of them is that there seems to be a direct interaction between both viruses, so HCV inhibits HBV replication, and that inhibition disappears when HCV is treated. Also it has been proposed that after HCV treatment there is more space available for HBV replication. The most accepted theory for the moment is that HCV replication makes a favourable immune situation in the organism, which is able to control HBV replication, and this situation is interrupted with DAAs treatment.

So, since the introduction of DAAs in 2014 and the big scale treatment of HCV patients, some isolated cases of HBV reactivation have been communicated, both in co-infected patients or with isolated anti-HBc, independently to the type of infection, which makes us consider the security of these therapies in co-infected HCV, HBV and HIV patients, as they seem to have no activity against HBV [12].

This is the first case described in literature of fulminant HBV reactivation leading to fulminant hepatic failure after HCV therapy with DAAs in a patient co-infected with HIV. It is unknown if the fact of having HIV infection has any relationship with reactivation or with the bad clinical evolution. Also, we need to take into account that a considerable number of co-infected HCV and HIV patients are
following nucleoside/nucleotide analogues treatment, which could prevent HBV reactivation after DAAs therapy.

References